(Updated - November 4, 2020 10:15 AM EST)

Biogen (NASDAQ: BIIB) shares spiked 14% and were halted due to volatility after FDA briefing documents for a review of Alzheimer's drug Aducanumab were posted.

Aducanumab was found to be effective enough to support approval, the FDA panel said in the documents.